Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03636373
Recruitment Status : Recruiting
First Posted : August 17, 2018
Last Update Posted : October 9, 2019
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Naomi Schlesinger, MD, Professor of Medicine, Rutgers, The State University of New Jersey

Brief Summary:
The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.

Condition or disease Intervention/treatment Phase
Gout Attack Drug: Etanercept Drug: Triamcinolone Acetonide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be administered a single dose of etanercept 50 mg subcutaneously (SC), at the onset of an acute gout attack, or a single dose of triamcinolone acetonide 40 mg intramuscularly (IM)
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Triple
Primary Purpose: Treatment
Official Title: Investigator-Initiated, Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
Actual Study Start Date : May 29, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout
MedlinePlus related topics: Gout

Arm Intervention/treatment
Experimental: Etanercept
Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
Drug: Etanercept
Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2

Active Comparator: Triamcinolone acetonide
Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
Drug: Triamcinolone Acetonide
Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2




Primary Outcome Measures :
  1. Joint pain intensity in the most affected joint [ Time Frame: 72 hours ]
    Pain intensity in the most affected baseline joint measured by the numeric 0-10 pain scale at 72 hours


Secondary Outcome Measures :
  1. Joint pain on numeric pain scale [ Time Frame: Days 4, 7, and 14 ]
    Patient's assessment of joint pain intensity in the most affected baseline joint on a 0-10 pain scale, at Baseline and post-dose Days

  2. Patient's assessment of response to treatment [ Time Frame: Day 4, 7 and 14 ]
    Patient's global assessment of response to treatment

  3. Physician's assessment of response to treatment [ Time Frame: Post-dose days 4, 7 and 14 ]
    Physician's global assessment of response to treatment

  4. Rescue Medication [ Time Frame: Days 4, 7, 14 ]
    Compare the use of rescue medication

  5. Safety and Tolerability of Etanercept [ Time Frame: During study ]
    Safety and tolerability as assessed by subjects with adverse events and serious adverse events from baseline through Visit 5 safety follow-up



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Male or female patients age ≥18 to ≤85 year
  2. History of established gout
  3. Onset of current acute gout attack within 4 days prior to randomization with: presence of any warm joint, swollen joint, pain score at rest ≥5 on the 0-10 pain scale, patient self-report of acute gout attack
  4. Baseline pain intensity ≥5 on a 0-10 pain scale;
  5. Tender (≥1 on a 0-4-point Likert scale) and swollen (≥1 on a 0-4-point Likert scale) index joint;
  6. If on urate-lowering therapy, a stable dose and regimen for at least 2 weeks prior to randomization, and expectance to remain on a stable dose and regimen for the duration of the double-blind treatment period, and;
  7. Body mass index (BMI) ≤45 kg/m2.

Exclusion Criteria:

  1. Use of intra-articular or IM corticosteroids within 14 days prior to screening;
  2. Use of an IL-1 inhibitor, TNF inhibitor or other biologic or investigational drug within 30 days prior to screening;
  3. History of a drug allergy to either study drug;
  4. Diagnosis or history of:

    1. rheumatoid arthritis (RA);
    2. infectious/septic or other inflammatory arthritis;
    3. alcoholic hepatitis or nonalcoholic steatohepatitis;
    4. immunodeficiency syndromes, including Human Immunodeficiency Virus (HIV) infection;
    5. Stage IIIb, IV, or V chronic kidney disease;
    6. idiopathic thrombocytopenic purpura;
    7. active, severe chronic pulmonary disease (eg, requiring oxygen therapy);
    8. uncontrolled hypertension (≥ 200/105 mmHg);
    9. symptomatic (New York Heart Association Class II, III, or IV) congestive heart failure;
    10. uncontrolled diabetes Type I or II (recent blood glucose > 300 mg/dL);
    11. myocardial infarction, unstable cardiac arrhythmias or unstable symptomatic coronary ischemia, within the past 12 months before randomization;
    12. history of malignancy of any organ system within the past 5 years;
    13. multiple sclerosis or any other demyelinating disease, or;
    14. major chronic inflammatory disease or connective tissue disease other than RA or psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.);
  5. Contraindication to IM injection;
  6. Donation or loss of ≥400 milliliters (mL) of blood in the 8 weeks before dosing;
  7. Any live vaccination in the 3 months before the start of the study;
  8. Active infection (including chronic or localized infections) for which antiinfectives were indicated within 4 weeks before screening;
  9. Any serious infection, defined as requiring hospitalization or intravenous anti-infectives, within 8 weeks before first dose of investigational product;
  10. Prosthetic joint infection within 5 years of screening, or native joint infection within 1 year of screening;
  11. Known alcohol addiction or dependency, daily alcohol use, or current substance use or abuse;
  12. Positive medical history for hepatitis B or C (subjects with a history of hepatitis B vaccination without history of hepatitis B infection are allowed to enroll);
  13. History of active tuberculosis;
  14. Positive test for tuberculosis during screening, defined as positive Purified Protein Derivative (PPD) skin test (≥5 mm induration at 48-72 hours after test is placed), or positive Quantiferon test;
  15. Pregnant or nursing (lactating) women
  16. Female patients who are physiologically capable of becoming pregnant must use an acceptable method of contraception

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03636373


Contacts
Layout table for location contacts
Contact: Naomi Schlesinger, MD 732 235 8378 schlesna@rwjms.rutgers.edu
Contact: Anoja Warusawithana, BS 732 235 6117 warusaan@rwjms.rutgers.edu

Locations
Layout table for location information
United States, New Jersey
Rutgers, Robert Wood Johnson Medical School, Clinical Research Center Recruiting
New Brunswick, New Jersey, United States, 08901
Contact: Deborah McCloskey, BSN    732-235-5965    mcclosda@rwjms.rutgers.edu   
Principal Investigator: Naomi Schlesinger, MD         
Sponsors and Collaborators
Rutgers, The State University of New Jersey
Amgen
Investigators
Layout table for investigator information
Principal Investigator: Naomi Schlesinger, MD Rutgers Robert Wood Johnson Medical School

Layout table for additonal information
Responsible Party: Naomi Schlesinger, MD, Professor of Medicine, Professor of Medicine, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier: NCT03636373     History of Changes
Other Study ID Numbers: Pro2018000562
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: October 9, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Gout
Arthritis
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Etanercept
Triamcinolone
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Enzyme Inhibitors